In addition, even in other tumor types, such as squamous lung carcinoma, sVEGFR-1/α5β1 integrin interaction was found to be involved in disease progression and lack of response to antiangiogenic agents, including the anti-VEGF-A mAb bevacizumab [38]. This evidence concerns the gene VEGFA and neoplasm.